Management of node-positive melanoma in the era of sentinel node biopsy

Rebekah R. White, Douglas Tyler

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Regional lymph node metastasis is a powerful predictor of decreased overall survival from malignant melanoma. However, the therapeutic value of elective node dissections and the role of adjuvant therapy for node-positive disease have been highly controversial. Sentinel lymph node biopsy has reshaped the debate by allowing for staging of the regional lymph nodes with less morbidity and greater accuracy. This review summarizes the current consensus on the management of node-positive melanoma in the era of sentinel lymph node biopsy.

Original languageEnglish (US)
Pages (from-to)119-125
Number of pages7
JournalSurgical Oncology
Volume9
Issue number3
DOIs
StatePublished - Nov 2000
Externally publishedYes

Fingerprint

Sentinel Lymph Node Biopsy
Melanoma
Lymph Nodes
Biopsy
Dissection
Neoplasm Metastasis
Morbidity
Therapeutics
cyhalothrin

Keywords

  • Adjuvant therapy
  • Lymph node dissection
  • Lymph node metastasis
  • Melanoma
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Management of node-positive melanoma in the era of sentinel node biopsy. / White, Rebekah R.; Tyler, Douglas.

In: Surgical Oncology, Vol. 9, No. 3, 11.2000, p. 119-125.

Research output: Contribution to journalArticle

@article{55f33123288d4cc8a16df491bc202be8,
title = "Management of node-positive melanoma in the era of sentinel node biopsy",
abstract = "Regional lymph node metastasis is a powerful predictor of decreased overall survival from malignant melanoma. However, the therapeutic value of elective node dissections and the role of adjuvant therapy for node-positive disease have been highly controversial. Sentinel lymph node biopsy has reshaped the debate by allowing for staging of the regional lymph nodes with less morbidity and greater accuracy. This review summarizes the current consensus on the management of node-positive melanoma in the era of sentinel lymph node biopsy.",
keywords = "Adjuvant therapy, Lymph node dissection, Lymph node metastasis, Melanoma, Sentinel lymph node biopsy",
author = "White, {Rebekah R.} and Douglas Tyler",
year = "2000",
month = "11",
doi = "10.1016/S0960-7404(00)00042-6",
language = "English (US)",
volume = "9",
pages = "119--125",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Management of node-positive melanoma in the era of sentinel node biopsy

AU - White, Rebekah R.

AU - Tyler, Douglas

PY - 2000/11

Y1 - 2000/11

N2 - Regional lymph node metastasis is a powerful predictor of decreased overall survival from malignant melanoma. However, the therapeutic value of elective node dissections and the role of adjuvant therapy for node-positive disease have been highly controversial. Sentinel lymph node biopsy has reshaped the debate by allowing for staging of the regional lymph nodes with less morbidity and greater accuracy. This review summarizes the current consensus on the management of node-positive melanoma in the era of sentinel lymph node biopsy.

AB - Regional lymph node metastasis is a powerful predictor of decreased overall survival from malignant melanoma. However, the therapeutic value of elective node dissections and the role of adjuvant therapy for node-positive disease have been highly controversial. Sentinel lymph node biopsy has reshaped the debate by allowing for staging of the regional lymph nodes with less morbidity and greater accuracy. This review summarizes the current consensus on the management of node-positive melanoma in the era of sentinel lymph node biopsy.

KW - Adjuvant therapy

KW - Lymph node dissection

KW - Lymph node metastasis

KW - Melanoma

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=0034447111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034447111&partnerID=8YFLogxK

U2 - 10.1016/S0960-7404(00)00042-6

DO - 10.1016/S0960-7404(00)00042-6

M3 - Article

C2 - 11356340

AN - SCOPUS:0034447111

VL - 9

SP - 119

EP - 125

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 3

ER -